On September 5, the awarding ceremony of the 4th "China Translational Medicine Award" was held in Beijing. Dr. Aimin Hui, Fosun Pharma's executive president, president of global R&D, and chief medical officer, was granted the 4th "China Translational Medicine Award - International Collaboration".

On June 19, 2021, the 27th Annual Meeting of Chinese Society of Dermatology (CSD) of Chinese Medical Association (CMA) was successfully held in Xi'an. During the meeting, a symposium on Han Da Yuan^® (Adalimumab Injection), Fosun Pharma's first biologics indicated for autoimmune disease, was grandly broadcast. For the symposium, Professor Xinghua Gao, the next president of the CMACSD and the vice president of the First Hospital of China Medical University, was invited to serve as the chairman, and Professor Yuzhen Li, from the Second Affiliated Hospital of Harbin Medical University, also a standing committee member of the CMACSD, was invited to serve as the speaker.

HLX04 is a bevacizumab biosimilar developed by Henlius independently in accordance with Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative), which can be used in the treatment of advanced, metastatic or recurrent non-small cell lung cancer(NSCLC) and metastatic colorectal cancer(mCRC).

Serplulimab injection is an innovative anti-PD-1 mAb independently developed by Henlius. Up to now, Serplulimab have been approved for clinical trials in China, the United States, the European Union, as well as other countries and regions.

HLX01 ( rituximab injection) is the first monoclonal antibody (mAb) biosimilar independently developed by Henlius and the first-ever China-manufactured biosimilar approved by the NMPA in accordance with the Technical Guidelines for the Development and Evaluation of Biosimilars (Tentative).

Recently, Biodrugs published the results of the global multicentre Phase 3 clinical trial (HLX02-BC01, NCT03084237 and EudraCT: 2016-000206-10) of 汉曲优^®, (trastuzumab, EU brand name: Zercepac^®) which was led by Professor Binghe Xu

At 11:00 p.m on November 19, 2020 (Beijing time), Fosun Pharma, together with two internationally renowned malaria experts, once again hosted a brilliant online academic conference for nearly 700 African medical workers, sharing the latest scientific advances in the prevention of maternal and childhood Malaria, and conducting a lively online Q&A session on related topics.

On November 22, 2020, the first "Ankylosing Spondylitis Standardized Medical Center (ASSC)" project in China, sponsored by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID),